INVA - Innoviva Inc logo

INVA

Innoviva Inc

Innoviva Inc develops and markets biopharmaceuticals, including respiratory treatments like RELVAR/BREO ELLIPTA and ANORO ELLIPTA, along with antibiotics such as XERAVA and ZEVTERA. The company focuses on managing royalties and developing new therapies.

βš•οΈ Healthcare NASDAQ Listed 2004 $ USD
$1,000 invested 20 years ago β†’$1,061today

Score Overview

1 Year
Score
Net Growth31.74%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth4.31%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score4.9
Net Growth34.37%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth13.16%
Rev Trend60%
Revenue Consistencyβ€”
10 Years
Score
Net Growth6x
Net Trend60%
Net Income Consistency
Rev Growth231.99%
Rev Trend80%
Revenue Consistency
20 Years
Score5.5
Net Growth315.15%
Net Trend70%
Net Income Consistency
Rev Growth22x
Rev Trend75%
Revenue Consistency
All Time
Score
Net Growth448.00%
Net Trend64%
Net Income Consistency
Rev Growth49x
Rev Trend77%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Innoviva Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • INVA

2015: 89.7% Β· 2021: 27.3% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 21.23β€”
1 Year2025-09-26
$ 18.8612.57%
5 Years2021-09-28
$ 17.2023.43%
10 Years2016-09-28
$ 11.2189.38%
20 Years2006-09-28
$ 20.006.13%
All Time2004-10-05
$ 13.5556.71%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 443M$ 357M$ 570M
2025$ 425M$ 271M$ 550M
2024$ 358M$ 23M$ 412M
2023$ 310M$ 179M$ 193M
2022$ 331M$ 213M$ 291M
2021$ 391M$ 265M$ 201M
2020$ 336M$ 224M$ 246M
2019$ 261M$ 157M$ 350M
2018$ 261M$ 395M$ 114M
2017$ 217M$ 134M$ 129M
2016$ 133M$ 59M$ 150M
2015$ 53M-$ 18M$ 187M
2014$ 8M-$ 168M$ 240M
2013$ 4M-$ 170M$ 465M
2012$ 5M-$ 18M$ 248M
2011$ 24M-$ 115M$ 240M
2010$ 24M-$ 83M$ 309M
2009$ 24M-$ 85M$ 155M
2008$ 23M-$ 93M$ 200M
2007$ 22M-$ 159M$ 126M
2006$ 19M-$ 166M$ 201M
2005$ 12M-$ 143M$ 161M
IPO2004$ 8M-$ 102M$ 257M
INVA - Innoviva Inc logo

Innoviva Inc fundamental performance

Between 2015 and 2025, revenue grew from $ 53M to $ 425M and net income went from -$ 18M to $ 271M. Revenue increased in 8 of those 10 years; net income in 6.

Between 2005 and 2025, revenue grew from $ 12M to $ 425M and net income went from -$ 143M to $ 271M. Revenue increased in 15 of those 20 years; net income in 14.

Innoviva Inc currently holds a 20-year HDB Score of 5.5 out of 10. How the HDB Score is calculated.

Membership

Continue INVA’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies